Hexima Limited. (ASX:HXL)

38.8¢

right-arrow Created with Sketch. -0.023 (-5.49%)
MCAP $67.74M
Last trade 15.20pm 18/01/2022 20mins delayed

Latest Announcements

04/01/2022HXLHexima Limited.
24/12/2021HXLHexima Limited.
24/12/2021HXLHexima Limited.
14/12/2021HXLHexima Limited.
14/12/2021HXLHexima Limited.
14/12/2021HXLHexima Limited.
14/12/2021HXLHexima Limited.
14/12/2021HXLHexima Limited.

Company Overview

Hexima Limited is an Australia-based clinical stage biotechnology company. The Company is engaged in the research and development of defensin peptides for applications as human therapeutics. The Company’s lead product candidate, pezadeftide applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections or onychomycosis. pezadeftide is under Australian Phase IIb clinical trial. It develops for the treatment of onychomycosis. The Company holds granted, long-life patents protecting pezadeftide in markets globally.

HXL in the news

Biotechnology company Hexima (HXL) successfully completes its share purchase plan (SPP) and…

Search Previous Announcements